Mepidental (Mepivacaine Hydrochloride)

Mepivacaine works by reversibly blocking voltage‑gated sodium channels on nerve membranes. This prevents the rapid influx of sodium ions needed for depolarization, thereby halting the transmission of pain signals from the site of injection to the central nervous system.

The appropriate dose of Mepidental is determined by the prescribing clinician based on the specific procedure, patient weight, age, and overall health. Dosing guidelines are provided in the product’s prescribing information and must be individualized for each patient.

The safety of mepivacaine during pregnancy or lactation has not been definitively established. It should only be used when the expected benefit outweighs any potential risk to the fetus or infant, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Mepivacaine is an amide‑type local anesthetic with a rapid onset and intermediate duration, similar to lidocaine but with slightly less vasodilatory effect. Compared with bupivacaine, it has a shorter duration and lower cardiotoxicity, making it suitable for shorter procedures where quick recovery of sensation is desired.

Mepidental should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from direct sunlight, moisture and extreme temperatures. Do not freeze the product, and keep it out of reach of children.

Mepidental is supplied as a sterile solution for injection. It is administered by infiltration directly into the target tissue or by perineural injection around a nerve. The injection technique and volume are determined by the clinician based on the intended anesthetic effect.

Serious risks include allergic reactions such as anaphylaxis, cardiovascular collapse, severe hypotension, cardiac arrhythmias, seizures, and methemoglobinemia. Immediate medical attention is required if any of these symptoms occur during or after administration.

Mepidental should be avoided in patients with known hypersensitivity to mepivacaine or other amide‑type local anesthetics, those with severe heart block, uncontrolled arrhythmias, or significant cardiovascular disease, and in individuals where the risk of systemic toxicity cannot be adequately managed.